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ABSTRACT
Aims/Introduction: Treatment intensification is commonly delayed in people with
type 2 diabetes, resulting in poor glycemic control for an unacceptable length of time
and increased risk of complications.
Materials and Methods: This retrospective study investigated clinical inertia in 33,320
Japanese adults with type 2 diabetes treated with oral antidiabetic drugs (OADs) between
2009 and 2018, using data from the Computerized Diabetes Care (CoDiC) database.
Results: The median time from first reported glycated hemoglobin (HbA1c) ≥7.0%
(≥53 mmol/mol) to treatment intensification was considerably longer and HbA1c levels
were higher the more OADs the patient was exposed to. For patients receiving three
OADs, the median times from HbA1c ≥7.0% (53 mmol/mol) to intensification with OAD,
glucagon-like peptide-1 receptor agonist or insulin were 8.1, 9.1 and 6.7 months, with a
mean HbA1c level at the time of intensification of 8.4%, 8.9% and 9.3%, respectively. The
cumulative incidence for time since the first reported HbA1c ≥7.0% (≥53 mmol/mol) to
intensification confirmed the existence of clinical inertia, identifying patients whose treat-
ment was not intensified despite poor glycemic control. HbA1c levels ≥7.0% (≥53 mmol/
mol) after ≥6 months on one, two or three OADs were observed in 42%, 51% and 58%
of patients, respectively, showing that approximately 50% of patients are above HbA1c tar-
get regardless of how many OADs they take.
Conclusions: Real-world data here show clinical inertia in Japanese adults with type 2
diabetes from early diabetes stages when they are receiving OADs, and illustrate a need
for earlier, more effective OADs or injectable treatment intensification and better commu-
nication around the existence of clinical inertia.
INTRODUCTION
It is estimated that approximately 10 million people in Japan
have “strongly suspected diabetes”1. Tight glycemic control in
people with type 2 diabetes is required to minimize the risk of
later complications2–5. Data from the Japan Diabetes Complica-
tions Study and the Japanese Elderly Diabetes Intervention
Trial6 showed that a 1%-point increase in the glycated hemo-
globin (HbA1c) level resulted in a significantly increased rela-
tive risk of micro- and macrovascular complications, with
hazard ratios of 1.22 (P = 0.03) and 1.23 (P = 0.02) for coro-
nary heart disease and stroke, respectively6.
As type 2 diabetes is progressive, maintenance of good glyce-
mic control necessitates that treatment is titrated or intensified
as time goes on7. Guidelines from the American Diabetes Asso-
ciation recommend initial treatment with the oral antidiabetic
drug (OAD), metformin, in combination with lifestyle modifi-
cations8. If an individualized HbA1c target is not achieved
within 3 months of treatment, and in the absence of atheroscle-
rotic cardiovascular disease or chronic kidney disease, treatment
should be intensified by the addition of further OADs (sulfony-
lurea [SU], thiazolidinedione, dipeptidyl peptidase-4 inhibitor
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[DPP-4i] or sodium–glucose cotransporter 2 inhibitor), gluca-
gon-like peptide-1 receptor agonists [GLP-1RAs] or basal insu-
lin8. Japanese Clinical Practice Guidelines are in agreement,
recommending that OADs and/or GLP-1RAs are given to non-
insulin-dependent patients in whom glycemic control is not
achievable with lifestyle modifications after 2–3 months, and
that insulin therapy should be started when glycemic goals are
no longer achievable with these9.
The American Diabetes Association, International Diabetes
Federation and Japanese Clinical Practice Guidelines recom-
mend setting an HbA1c goal of <7.0% (<53 mmol/mol) in
the majority of (non-pregnant) adults with type 2 diabetes8–10.
The American Association of Clinical Endocrinologists sup-
ports a slightly more stringent HbA1c goal of ≤6.5%
(≤48 mmol/mol) for most patients11. The American Diabetes
Association and Japanese Clinical Practice Guidelines recom-
mend more stringent goals (<6.5% [<48 mmol/mol] and
<6.0% [<42 mmol/mol], respectively) for selected individuals if
achievable without significant hypoglycemia or other adverse
effects8,9, but a less stringent goal of <8.0% (<64 mmol/mol)
in elderly patients or those with, for example, a history of
severe hypoglycemia, advanced vascular complications or
extensive comorbidities9,12.
Multiple studies have shown evidence of clinical inertia
(inappropriately delayed treatment intensification) in people
with type 2 diabetes, resulting in poor glycemic control for an
unacceptable length of time13,14. A large retrospective cohort
study of 81,573 people with type 2 diabetes in the UK treated
with one, two or three OADs showed that in people with
HbA1c ≥7.0% (≥53 mmol/mol), ≥7.5% (≥58 mmol/mol) or
≥8.0% (≥64 mmol/mol), the median time from above HbA1c
cut-off to intensification with an additional OAD was 2.9, 1.9
or 1.6 years, respectively, for those taking one OAD, and >7.2,
>7.2 and >6.9 years for those taking two OADs15. Data show
that people with type 2 diabetes are receiving treatment with
multiple OADs for long periods of time before their treatment
is intensified, despite poor glycemic control. Several studies
have also shown that clinical inertia exists in people with type 2
diabetes treated with OADs who are starting insulin therapy15–
18.
The Computerized Diabetes Care (CoDiC) database was
developed by the Japan Diabetes Clinical Data Management
Study Group (JDDM) to promote clinical research on diabetes.
This large, anonymized, longitudinal, validated database, which
is updated annually, contains patient-level clinical information
for approximately 60,000 patients treated by diabetes specialists
in 61 JDDM participating diabetes institutions across Japan,
including diagnosis, mortality, laboratory results and prescrip-
tion data.19 A cross-sectional study using data from the
CoDiC database investigated changes in OAD prescriptions
and improved glycemic control from 2002 to 2011 in Japan.20
The results showed a move toward polypharmacy, particularly
including biguanides and DPP-4is, accompanied by an
improvement in HbA1c levels20. Another recent, retrospective
cohort study using data from the CoDiC database showed
that clinical inertia existed in Japanese clinical practice among
people with type 2 diabetes treated with basal insulin21.
Clinical inertia is a global problem, the extent of which has
been shown to vary between countries22–25. The aim of the pre-
sent retrospective study was to investigate clinical inertia in
Japanese adults with type 2 diabetes treated with OADs, using
prescription data from the CoDiC database, including how
and when they received treatment intensification.
METHODS
Study design and participants
This retrospective analysis was carried out using data extracted
from the CoDiC database19 by the JDDM Study Group.
Retrieved data included prescriptions of antidiabetic medication
(including drug name, dose and frequency), prescriptions of
selected other medications and drug category, patient visit and
examination results, and patient characteristics including date of
birth, sex, diagnosis date of type 2 diabetes, and date for the
first contact recorded in the CoDiC. Patients were included in
the overall study population if they had a diagnosis of type 2
diabetes, were aged ≥18 years, and had at least one OAD pre-
scription in the period between 1 January 2009 and 31 Decem-
ber 2011. Only individuals with an available first visit date were
included. In cases where the first visit date was after the first
prescription, the individual was excluded. Follow up started
from the first OAD prescription between 2009 and 2011, and
was until 12 March 2018. Only OAD regimens that started
>91 days after the start of the observation period were included
to ensure that they were not ongoing regimens. The JDDM
ethics committee approved the study protocol. Written
informed consent was not required from patients because of the
retrospective nature of this study. The option to “opt out” and
how to do it were made clear through a poster in each clinic
describing the study (available here [Japanese]: http://jddm.jp/).
End-points
The protocol-specified primary end-point was time from the
start of an OAD regimen (limited to one, two or three OADs)
to a treatment change. Treatment change comprised the addi-
tion of one or more OADs, insulin, GLP-1RA or GLP-1RA
plus insulin (representing treatment intensification), change in
OADs not consisting of OAD addition, discontinuation of
OAD (none of which qualified as treatment intensification), or
no further prescription information being available.
The main secondary end-point, a subset of the primary end-
point dataset providing a measure of clinical inertia, was time to
treatment change (as described above), or HbA1c <7.0%, from
the first HbA1c above target (HbA1c ≥7.0% [≥53 mmol/mol])
after ≥6 months of taking OADs. Additional end-points included
HbA1c level at time of intensification, and the proportion of
patients with an HbA1c level above target (using HbA1c ≥7.0%
[≥53 mmol/mol], ≥7.5% [≥58 mmol/mol] or ≥8.0% [≥64 mmol/
mol] as the cut-off) after ≥6 months of taking OADs.
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Additional analyses investigated the proportion of patients
with HbA1c ≥7.0% (53 mmol/mol) after ≥6 months of taking
OADs, stratified by the most frequent types of OAD received
(i.e., metformin, SU or DPP-4i for one OAD; metformin + SU,
SU + DPP-4i or metformin + DPP-4i for two OADs;
SU + metformin + DPP-4i, SU + metformin + alpha-glucosi-
dase or SU + metformin + thiazolidinedione for three OADs).
Additional analyses were also carried out on differences in out-
comes between OAD regimens containing DPP-4is and those
without, given their frequent use in Japan.
Statistical analysis
Data were analyzed for each of the OAD regimens (comprising
of one, two or three OADs). Only the first instance of repeated
OAD regimens was used in the analysis. No adjustment for
multiplicity was carried out. All outcomes, exposure and con-
founding variables were reported using descriptive statistics.
Time from the start of an OAD regimen to treatment
change, and time to treatment change or HbA1c <7.0% from
the first HbA1c ≥7.0% (≥53 mmol/mol), after ≥6 months of
taking OADs, were analyzed as time-to-event data with com-
peting risks for estimation of the cumulative incidence function.
The causes were derived from the status at the end of the
OAD regimen, with the exception of using censoring for no
further information when the end date was on or after 1 Jan-
uary 2018. The estimated cumulative incidence function was
presented graphically for all causes, and in tabular format for
treatment intensification causes and selected timepoints. The
HbA1c level at time of treatment intensification was reported
using the mean and standard deviation.
RESULTS
Over the course of the study, 10,217, 13,061 and 10,042 partici-
pants (with at least one OAD prescription between 1 January
2009 and 31 December 2011) were exposed to regimens with
one, two or three OADs, respectively. The most frequently
reported OADs were biguanides, SUs or DPP-4is for regimens
containing one OAD (~25% for each); SUs + biguanides (23%)
for regimens containing two OADs; and SUs + biguanides +
DPP-4i (38%) for regimens containing three OADs (Table S1).
The baseline characteristics of participants exposed to one,
two or three OADs are presented in Table S2. Two-thirds of
the participants in each group were men, the mean age at
OAD regimen start ranged 62–63 years across the groups and
42–45% of the participants were aged ≥65 years (Table S2).
The mean time from documented diabetes onset to starting an
OAD regimen ranged 8.9–12.1 years, with a mean HbA1c level
before starting an OAD regimen ranging 7.7–8.0% (Table S2).
The median time to treatment intensification from the first
reported HbA1c value ≥7.0% (53 mmol/mol) and mean HbA1c
at time of intensification are shown in Table 1. Time to intensi-
fication with any treatment was considerably longer and HbA1c
levels were higher the more OADs the patient was exposed to,
and intensification with insulin was generally carried out earlier
compared with other intensification options. For participants
taking one OAD, the median times from the first reported
HbA1c value ≥7.0% (53 mmol/mol) to intensification with
OAD, GLP-1RA or insulin alone were 3.7, 5.6 and 3.3 months,
with a mean HbA1c level at the time of intensification of 8.1%,
7.8% and 9.3%, respectively. For participants taking three
OADs, the median times from HbA1c ≥7.0% (53 mmol/mol)
to intensification were 8.1, 9.1 and 6.7 months, respectively,
with a mean HbA1c level at the time of intensification of 8.4%,
8.9% and 9.3%.
The cumulative incidence for time since the first reported
HbA1c value ≥7.0% (53 mmol/mol) to treatment intensification
in patients taking one, two or three OADs is shown in
Figure 1. The grey area shows patients whose treatment was
not intensified, despite having an HbA1c ≥7.0% (53 mmol/
mol), giving a clear measure of the extent of clinical inertia
Table 1 | Median time to treatment intensification* from the first glycated hemoglobin ≥7.0% (≥53 mmol/mol) after 6 months of treatment, and
mean glycated hemoglobin at the time of intensification
1 OAD (n = 3,960) 2 OADs (n = 6,278) 3 OADs (n = 5,615)
Median time in months (range) from the first HbA1c ≥7.0% (≥53 mmol/mol) to treatment intensification with:
OAD add-on 3.7 (0.1–76.3) (n = 1,257) 5.7 (0.1–81.3) (n = 1,538) 8.1 (0.1–82.7) (n = 626)
GLP-1RA 5.6 (0.9–28.8) (n = 18) 5.8 (0.1–36.2) (n = 32) 9.1 (0.1–74.3) (n = 76)
Insulin 3.3 (0.1–35.2) (n = 37) 4.3 (0.1–61.0) (n = 78) 6.7 (0.1–66.3) (n = 151)
1 OAD (n = 3,762) 2 OADs (n = 5,997) 3 OADs (n = 5,348)
Mean HbA1c % (SD) at the time of intensification (after HbA1c ≥7.0% [≥53 mmol/mol]) with:
OAD add-on 8.1 (1.0) (n = 1,257) 8.3 (1.0) (n = 1,538) 8.4 (1.0) (n = 626)
GLP-1RA 7.8 (0.6) (n = 18) 9.2 (1.3) (n = 32) 8.9 (1.3) (n = 76)
Insulin 9.3 (2.0) (n = 35) 9.4 (1.9) (n = 78) 9.3 (1.4) (n = 151)
*The main secondary end-point was time to treatment change (comprising the addition of one or more oral antidiabetic drug [OADs], insulin, glu-
cagon-like peptide-1 receptor agonist [GLP-1RA] or GLP-1RA plus insulin [representing treatment intensification, as reported here], change in OAD
dose or brand, discontinuation of OAD, no further prescription information being available, censoring or glycated hemoglobin [HbA1c] <7.0%) from
the first HbA1c ≥7.0% (≥53 mmol/mol) after ≥ 6 months of taking OADs. SD, standard deviation.
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(Figure 1). As expected, the level of clinical inertia increased
the more OADs the patient was exposed to.
The median time from the start of an OAD regimen to
treatment intensification and mean HbA1c values at that time
are shown in Table 2. The time from the start of an OAD regi-
men to intensification with any OAD treatment was again con-
siderably longer the more OADs the patient was exposed to.
The cumulative incidence function for time since regimen start
to intensification is shown in Table S3 for causes related to
treatment intensification and selected timepoints.
The proportion of patients with an HbA1c value ≥7.0%
(≥53 mmol/mol), ≥7.5% (≥58 mmol/mol) or ≥8.0%
(≥64 mmol/mol) after ≥6 months on an OAD regimen is
shown in Table 3. An HbA1c value ≥7.0% (≥53 mmol/mol)
after ≥6 months of taking OADs was reported in 42%, 51%
and 58% of patients taking one, two and three OADs, respec-
tively, indicating that there was still a large proportion of
uncontrolled patients taking multiple OADs. Stratification of
these data by the most frequent type of OAD used showed
similar proportions of patients with uncontrolled disease
(Table S4). In patients taking one OAD, HbA1c ≥7.0%
(≥53 mmol/mol) was reported for 46%, 44% and 45% of
patients intensified with metformin, SU and DPP4-i, respec-
tively. The proportion of patients with HbA1c ≥7.0%
(≥53 mmol/mol) was generally lower in older people (37%,
46% and 52%, respectively, in patients aged ≥ 75 years taking
one, two or three OADs; Table 3). An HbA1c level ≥7.5%
(≥58 mmol/mol) after ≥6 months of taking OAD was observed
in 27%, 36% and 44% of patients, and an HbA1c ≥8.0%
(≥64 mmol/mol) in 15%, 21% and 29% of patients taking one,
two or three OADs, respectively (Table 3).
The median time from the first HbA1c ≥7.0% (≥53 mmol/
mol) to treatment intensification was longer for patients on regi-
mens containing three OADs that included DPP-4is (Table S5).
DISCUSSION
Both international and Japanese consensus guidelines for the
management of type 2 diabetes recommend an individualized
stepwise approach to intensifying treatment8,9. The guidelines
stipulate that treatment should be re-evaluated every 3–
6 months to avoid clinical inertia8.
Using the CoDiC database, the present study investigated
clinical inertia and treatment intensification in Japanese people
with type 2 diabetes treated with one, two or three OADs. The
most frequent components of the studied OAD regimens were
biguanides, such as metformin, SU and DPP-4i, in alignment
with what is seen in routine clinical practice.
The time to intensification, with any treatment, from the first
HbA1c value reported to be out of control (≥7.0% [≥53 mmol/
mol]) was considerably longer the more OADs the patient was
exposed to. Cumulative incidence data showing the proportion
of patients whose treatment was not intensified despite having
an HbA1c level ≥7.0% (≥53 mmol/mol), that is, omitting data






































1 OAD 2 OADs 3 OADs
GLP-1RA added Insulin added
Event free
GLP-1RA and insulin added
No further informationOther OAD change
1 2 3 4 5
Time from HbA1c ≥ 7.0% (≥ 53 mmol/mol) to event (years)
0 1 2 3 4 5 0 1 2 3 4 5
HbA1c <7.0% (<53 mmol/mol)
Figure 1 | Cumulative incidence for time since the first reported glycated hemoglobin (HbA1c) value ≥7.0% (≥53 mmol/mol) to first event in
patients taking one, two or three OADs. GLP-1RA, glucagon-like peptide-1 receptor agonist; OAD, oral antidiabetic drug.
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the existence of clinical inertia in this population. As might be
expected, a higher HbA1c was observed at the time of intensifi-
cation in those patients on regimens comprising of three
OADs, compared with those taking one or two OADs, indica-
tive of the disease progression in those individuals. The median
time from the start of an OAD regimen to treatment intensifi-
cation with any OAD treatment was also considerably longer,
and HbA1c levels were higher the more OADs the patient was
exposed to.
In patients taking three OADs, treatment was intensified
after a median of 8.1 months with an OAD, 9.1 months with a
GLP-1RA and 6.7 months with insulin. These findings high-
light the issue of clinical inertia in this OAD polypharmacy
population, particularly for those patients whose healthcare pro-
fessionals might not want to consider initiating insulin or GLP-
1RA therapy. Data show that people with type 2 diabetes can
be treated ineffectively with OADs for a long time. More effec-
tive OADs and strategies are required to reduce clinical inertia
and improve long-term glycemic control in these patients.
HbA1c levels ≥7.0% (≥53 mmol/mol) after ≥6 months on an
OAD regimen comprising one, two or three OADs were
observed in 42%, 51% and 58% of patients, respectively,
showing that approximately 50% of patients are above HbA1c
treatment target regardless of the number of OADs they take.
The data presented here show persistently high HbA1c levels
despite OAD treatment, and extensive delays in treatment
intensification in patients taking one, two or three OADs.
Additional analyses stratified by the most frequent type of
OADs used did not show any differences in reaching glycemic
targets, and the proportions of patients with uncontrolled dis-
ease were similar to the overall population.
Interestingly, the findings reported here show a lower degree
of clinical inertia compared with those reported by Khunti
et al.15 from a large retrospective cohort study of people with
type 2 diabetes in the UK treated with one, two or three
OADs. Results from that study showed that in people with
HbA1c ≥7.0% (≥53 mmol/mol), ≥7.5% (≥58 mmol/mol) or
≥8.0% (≥64 mmol/mol), the median time from above the
HbA1c cut-off to intensification with an additional OAD was
2.9, 1.9 and 1.6 years, respectively, for those taking one OAD,
and <7.2, <7.2 and <6.9 years, respectively, for those taking
two OADs15. Differences in clinical inertia between the two
studies could be explained by variation in healthcare systems
and potential differences in population demographics. In the
Table 2 | Median time from start of an oral antidiabetic drug regimen to treatment intensification* and mean glycated hemoglobin at the time of
intensification
1 OAD (n = 10,209) 2 OADs (n = 13,054) 3 OADs (n = 10,038)
Median time in months (range) from the start of OAD regimen to intensification with:
OAD add-on 6.2 (0–95.2) (n = 4,773) 9.9 (0–95.4) (n = 4,122) 18.0 (0–92.0) (n = 1,407)
GLP-1RA 5.1 (0–67.6) (n = 86) 7.8 (0.2–45.3) (n = 83) 16.1 (0.1–90.8) (n = 138)
Insulin 2.0 (0–68.7) (n = 240) 4.2 (0–69.1) (n = 284) 9.5 (0.1–74.7) (n = 305)
1 OAD (n = 8,081) 2 OADs (n = 11,104) 3 OADs (n = 8,653)
Mean HbA1c % (SD) at the time of intensification with:
OAD add-on 7.9 (1.2) (n = 4,435) 8.0 (1.1) (n = 3,917) 8.1 (1.0) (n = 1,356)
GLP-1RA 7.9 (1.5) (n = 65) 8.6 (1.5) (n = 75) 8.6 (1.3) (n = 125)
Insulin 8.7 (2.0) (n = 167) 9.1 (1.9) (n = 230) 9.2 (1.6) (n = 277)
*The primary end-point was the time from the start of an oral antidiabetic drug (OAD) regimen to treatment change (comprising addition of one
or more OADs, insulin, glucagon-like peptide-1 receptor agonist [GLP-1RA] or GLP-1RA plus insulin [representing treatment intensification, as
reported here], change in OAD dose or brand, discontinuation of OAD, no further prescription information being available, or censoring). HbA1c,
glycated hemoglobin; SD, standard deviation.
Table 3 | Proportion of patients with glycated hemoglobin ≥7.0% (≥53 mmol/mol), ≥7.5% (≥58 mmol/mol) or ≥8.0% (≥64 mmol/mol), after
≥6 months on an OAD regimen




















1 OAD 41.7% 44.3% 43.7% 38.8% 36.7% 27.1% 23.4% 15.2%
2 OADs 50.5% 50.3% 52.2% 48.6% 46.0% 35.9% 32.8% 21.4%
3 OADs 58.0% 59.2% 60.6% 54.9% 52.0% 44.1% 39.3% 28.7%
HbA1c, glycated hemoglobin; OAD, oral antidiabetic drug.
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latter study, a lower proportion of participants were men (51–
57% across groups), compared with two-thirds of participants
in the present study, and the mean baseline HbA1c levels
before starting an OAD regimen were substantially higher
(8.4%, 8.8% and 9.0% in people taking one, two or three
OADs) compared with the present study (7.7%, 7.9% and
8.0%, respectively). A large-scale survey of Japanese type 2 dia-
betes patients in primary care, in which 53% had HbA1c levels
<7.0% (<53 mmol/mol) and the mean HbA1c was 7.04%, also
suggests comparatively good glycemic control in this popula-
tion26.
Japan is now facing a super-aged society, and the number of
elderly patients with diabetes is rising steadily. Elderly patients
might experience cognitive impairment or dementia, and have
a tendency to suffer from severe hypoglycemia27. Guidelines
from the Joint Committee of the Japan Diabetes Society and
the Japan Geriatrics Society for Improvement in Treatment of
Elderly Patients with Diabetes recommend that, if treatment
intensification is difficult in an elderly patient, for example, due
to moderate dementia, the target HbA1c should be set at
<8.0% (<64 mmol/mol)9.
The impact of setting different glycemic targets (HbA1c
<7.5% and HbA1c <8.0%) on all end-points was analyzed, but
it was beyond the scope of this article to present all the data
here. However, the impact of varying the target definition
across age subgroups is presented in Table 3, acknowledging
that a uniform glycemic target might not be appropriate for all
patients. Additional analyses according to age at the start of an
OAD regimen (or after ≥6 months of treatment) were also
beyond the scope and objectives of this study, but might be
interesting for future research.
The limitations of the present study were that only descrip-
tive data were reported, with no statistical significance testing,
and the results were retrospective and limited to Japan. Gener-
alized conclusions made from this study to other populations
or countries should be done with caution. In addition, treat-
ment intensification and HbA1c values were not analyzed as a
function of patient comorbidities/diabetic complications, which
allow for a less stringent HbA1c goal. Finally, some of the
DDP-4is used only became available part-way through the
study, and therefore might have been misrepresented. The
median time from the start of an OAD regimen to treatment
intensification was longer for patients on regimens containing
DPP-4is than for those not receiving DPP-4is. The median
time from the first HbA1c ≥7.0% to treatment intensification
was also longer for patients on regimens containing three
OADs that included DPP-4is. It would be useful to carry out
further, larger analyses of the impact of availability of DPP-4is
on clinical inertia. The study period also resulted in sodium–
glucose cotransporter 2 inhibitors not being reflected to an
extent that matches their current magnitude of use. The chang-
ing treatment landscape for diabetes, including the expected
launch of oral GLP-1RA and combination treatments, might
have a significant effect on clinical inertia in the future. Finally,
it was beyond the scope of this study to assess treatment adher-
ence. The level of adherence to diabetes treatment might have
influenced subsequent intensification and, thus, the extent of
clinical inertia28.
Increasing awareness might be key to minimizing clinical
inertia in the treatment of type 2 diabetes. The Time2DoMore
study, an online survey of 652 adults with diabetes and 337
treating physicians in six countries, concluded that impairment
in communication is at the heart of clinical inertia29. It is
important to assess the extent of clinical inertia in clinical prac-
tice in different regions, so that strategies to improve clinical
care and outcomes can be implemented30. As the majority of
patients in Japan are treated in a clinic rather than a hospital
setting, the CoDiC database is considered representative of
the diabetes population in Japan. Furthermore, the CoDiC
database has previously been used to study clinical inertia in
Japanese adults with type 2 diabetes treated with basal insu-
lin20,21.
Real-world data presented here show that clinical inertia
exists in Japanese adults with type 2 diabetes from early stages
of the disease when they are receiving treatment with OADs,
and illustrate a need for earlier, more effective OAD or inject-
able treatment intensification, setting of individual treatment
goals and better communication around the existence of clinical
inertia. Strategies are needed to increase the number of patients
undergoing effective therapy intensification and to reduce the
delay in treatment intensification in Japan.
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Table S2 | Baseline characteristics of participants exposed to one, two or three oral antidiabetic drugs.
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